Pliant cuts workforce by 45% following lung trial termination
Pliant Therapeutics will cut 45% of its workforce in a sweeping restructuring effort aimed at extending its cash runway, the …
-
-
Q1 earnings pulse check: companies tentative on pharma-specific tariffs
While many pharmaceutical companies have calculated cost hits associated with US tariffs, they are reiterating that looming pharma-specific tariffs create …
-
MHRA authorises Bavarian Nordic’s chikungunya virus vaccine
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation to Bavarian Nordic's Vimkunya (recombinant, adsorbed) vaccine …
-
Entering the era of prenatal gene therapies
In February 2025, researchers at St Jude Children’s Research Hospital reported the first known in utero use of Roche’s spinal …
-
HHS launches $500m universal vaccines initiative
The US Department of Health and Human Services (HHS) has launched a $500m initiative to accelerate the development of universal …
-
FDA awards RMAT status to 4DMT diabetic macular oedema therapy
4D Molecular Therapeutics (4DMT) has received regenerative medicine advanced therapy (RMAT) designation from the US Food and Drug Administration (FDA) …
-
PTSD market expected to reach $5.5bn across the 7MM by 2034
The post-traumatic stress disorder (PTSD) market is expected to grow at a high compound annual growth rate of 16.1% from …
-
Repare signs out-licensing deal with DCx Biotherapeutics
Repare Therapeutics has entered an out-licensing agreement with Canadian biotechnology firm DCx Biotherapeutics for discovery platforms and intellectual property (IP). Repare …
-
Biogen’s Q1 revenue soars past estimates as rare disease pivot pays off
Biogen has unveiled Q1 2025 revenues above estimates, spurred by strong sales of rare disease assets amid a sales dropoff …
-
Lilly’s Q1 2025 revenue jumps 45%, but CVS shift boosts Novo’s Wegovy
Eli Lilly has reported $12.73bn in Q1 2025 revenue, a 45% increase from the prior year, driven largely by demand …
-
New £1bn cancer research hub planned for South London
Plans have been unveiled for The London Cancer Hub, a state-of-the-art cancer research and laboratory hub to be located in …
-
Dimerix and Amicus to commercialise DMX-200 in US
Australian biopharmaceutical company Dimerix and Amicus Therapeutics have signed an agreement for the US commercialisation of the former’s Phase III …
-
End-to-end solutions: why every link in the pharmaceutical supply chain counts
Every stage of the pharmaceutical supply chain is critical if life-saving drugs are to make it to market – and …
-
GSK remains resilient on tariffs as Q1 sales rise 4%
GSK said it remains confident in its ability to absorb the financial impact of potential US pharmaceutical tariffs as it …
-
Novartis to strengthen renal disease portfolio with Regulus
Novartis has agreed to acquire US-based Regulus Therapeutics and its oligonucleotide, farabursen, to bolster its renal disease offerings. The upfront cash …
